Vertex Pharmaceuticals Inc. buy stratec
Start price
14.01.18
/
50%
€142.77
Target price
11.01.19
€170.18
Performance (%)
18.71%
End price
11.01.19
€169.48
Summary
This prediction ended on 11.01.19 with a price of €169.48. The prediction had a final performance of 18.71%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 5.141% | 5.141% | -3.235% | 39.408% |
| iShares Core DAX® | -1.673% | 2.237% | 16.344% | 61.776% |
| iShares Nasdaq 100 | -1.346% | 0.290% | 3.851% | 105.171% |
| iShares Nikkei 225® | -1.529% | 5.863% | 18.286% | 52.222% |
| iShares S&P 500 | -1.702% | 0.697% | 1.755% | 66.580% |
Comments by stratec for this prediction
In the thread Vertex Pharmaceuticals Inc. diskutieren
Vertex wins expanded approval for its cystic fibrosis combo
Looking forward: VRTX moves the needle here with this approval. Now, it would appear as though the European approval matches that in America, and this can be a good tool for young patients with this form of cystic fibrosis. The $250,000+ price tag on Orkambi means that even with only reaching a third of the patients, the company stands to gain hundreds of millions in revenue a year from this.
stratec stimmt am 14.01.2018 der Outperform-Einschätzung der institutionellen Analysten aber mit dem Kursziel 188,67$ zu.
(Vom Mitglied beendet)
Stopped prediction by stratec for Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€414.00
09.04.25
09.04.25
€480.00
09.04.26
09.04.26
-5.02%
13.01.26
13.01.26
